A Study of HS-20124 in Patients with Advanced Solid Tumors

HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20124 in Patients With Advanced Solid Tumors.

NCT Number	NCT06763159
Lead Sponsor	Hansoh BioMedical R&D Company
Conditions	Solid Cancer
Enrollment	450 participants
Start Date	2024-10-30
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-01-08